In this Policy Forum article, James A. Watson and colleagues discuss recent guidelines relating to pre-referral treatment of suspected severe malaria with rectal artesunate suppositories in remote areas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681301 | PMC |
| http://dx.doi.org/10.1371/journal.pmed.1004312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Indigenous emergence and spread of C469Y artemisinin-resistant in Uganda.
Antimicrob Agents Chemother
August 2024
Malaria Research Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia.
Article Synopsis
- Artemisinin-based combination therapies (ACTs) have been the standard treatment for uncomplicated malaria in Africa for nearly 20 years, but recent studies indicate an increase in mutant parasites linked to reduced treatment effectiveness.
- The Community Access to Rectal Artesunate for Malaria project studied 697 children with severe malaria in northern Uganda, finding that a significant mutation (C469Y) was more common after the introduction of rectal artesunate, suggesting it enhances resistance.
- Genome analysis revealed that the C469Y mutation has an indigenous African origin and confirmed that parasites with this mutation show significantly reduced susceptibility to artemisinin, highlighting the urgent need for ongoing monitoring and adherence to treatment protocols to combat the rise of resistant strains.
Severe malaria intervention status in Nigeria: workshop meeting report.
Malar J
June 2024
National Malaria Elimination Programme, Public Health Department, Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.
Nigeria accounts for 39% of global malaria deaths in children under 5 years of age and the effective management of severe malaria is a health priority. The Annual Nigeria Severe Malaria Stakeholders Workshop, held on the 5-6th of July 2023 in Abuja, Nigeria brought together representatives from 36 States, the Federal Capital Territory, and other key stakeholders to address the management of severe malaria across all levels of the health service. Aims were to provide updates and review progress on severe malaria activities, the burden of disease, commodity logistics management, and pre-referral national policy implementation as well as to disseminate research findings.
View Article and Find Full Text PDFDefining the next generation of severe malaria treatment: a target product profile.
Malar J
June 2024
Medicines for Malaria Venture, Route de Pré-Bois 20, Post Box 1826, CH-1215, Geneva 15, Switzerland.
Background: Severe malaria is a life-threatening infection, particularly affecting children under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives is highly efficacious. However, artemisinin partial resistance is widespread in Southeast Asia, resulting in delayed parasite clearance after therapy, and has emerged independently in South America, Oceania, and Africa.
View Article and Find Full Text PDFRectal artesunate: lives not saved.
Trans R Soc Trop Med Hyg
October 2024
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.
Where will rectal artesunate suppositories save lives?
Lancet
March 2024
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!